A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

Inclusion Criteria: * Male patients age ≥18 years old * Histologically confirmed adenocarcinoma of the prostate * Adequate organ function including: * \- Platelet count of \> 50,000/mm3 * \- Neutrophil count of \> 1000/mm3 * \- Serum Cr \< 1.5 x ULN or estimated GFR \> 60 ml/min based upon Cockroft-Gault equation * \- Proteinuria \< 1 g/24 hours based upon 24 hour urine collection or spot urine protein/creatinine ratio * \- AST and ALT \< 2.5 x ULN (\< 5 x ULN in patients with known liver metastases) * \- Total bilirubin \< 1.5 x ULN (\< 3 x ULN in patients with known/suspected Gilbert's disease) * ECOG performance status of 0 or 1 * Able to provide written informed consent and willing to comply with protocol requirements * No contra-indication to MR including severe claustrophobia, incompatible aneurysm clips or cardiac pacemaker * For men of childbearing potential, the use of effective contraceptive methods during the trial and within 6 months following radiotracer injection * Cohort A only (N = 5 evaluable patients):- Planned radical prostatectomy within 12 weeks following protocol scan * \- No androgen deprivation, anti-androgen therapy, chemotherapy, or investigational systemic therapy prior to CTT1057 PET imaging * Cohort B only:- Presence of at least three distinct metastatic lesions by standard imaging including whole body bone scan + cross-sectional imaging of the abdomen and pelvis obtained within 12 weeks prior to protocol scan * \- Castration-resistant disease as defined by PCWG2 criteria * \- Must remain on androgen deprivation therapy for duration of trial if no prior bilateral orchiectomy Exclusion Criteria: * Inadequate venous access per assessment of treating health care provider * Receipt of radioisotope within 5 physical half lives prior to trial enrollment * Prior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 days * Have a medical condition or other circumstances that, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the trial. * Histologic evidence of small cell prostate cancer or neuroendocrine differentiation in \> 50% of biopsy tissue